However, the clinical application of anabolic agents (e.g., GH/IGF-1 axis modulators) is significantly constrained by their potential tumor-promoting effects, necessitating rigorous benefit–risk assessment—particularly in hormone-sensitive malignancies (e.g., breast and prostate cancers) (32). This evidence concerns the gene IGF1 and prostate cancer.